[PDF] Top 20 Plan estratégico de la empresa Delta/Signal para el periodo 2019-2022

... that aflibercept is available for AMD, physicians considering a change in drugs will need to consider several ...to aflibercept with its expected longer duration of action is a reasonable ... See full document

... such clinical outcomes, our analysis reveals for the first time that patients (based on ophthalmologist feedback) are also able to tangibly experience the effectiveness of anti-VEGF treatment with T&E, ... See full document

... the clinical data on which the model was based were drawn predominately from people whose worse-seeing eye (WSE) had been ...the utility model corresponds to the eye that is being ... See full document

... Abstract: Wet age-related macular degeneration (AMD) is the most common reason for vision loss in the United ...scale. Aflibercept, another new therapy known to trap VEGF ... See full document

... and aflibercept suggesting that both drugs could be used as first line ...the clinical niches where the two drugs show their optimal efficacy ...Aflibercept’s utility as a ‘salvage therapy’ in cases ... See full document

... following criteria: 1) active subfoveal choroidal neovascu- larization (CNV) secondary to exudative AMD confirmed by fluorescein angiography; 2) E-ETDRS vision of 25–80 letters (Snellen equivalent of ~ 20/25 to 20/320); ... See full document

... with wet AMD and prescribed IVT-AFL by their physician were ...or macular laser in the study eye was not ...diabetic macular oedema, myopic choroidal neovascularisation, retinal vein occlusion, ... See full document

... In this study, we estimated the proportion of patients treated for ocular pathologies with anti-VEGF therapy and needing bilateral injections over a 1-month period. Our data show that the rate of bilateral ... See full document

... central macular thickness (CMT), the presence of dome-shaped pigment epithelial detachment (PED), the presence of an obvious RPE discontinuity, and the presence of subretinal or intraretinal ... See full document

... anxiety related to treatment is more frequent in patients who have received up to 3 injections than in patients who have received more injections, ...anti- VEGF (Group 3, ...indicating clinical ... See full document

... Ophthalmological examination of the patients in both study groups was carried out (visual acuity, slit biomicroscopy, intraocular pressure, dilated fundoscopy, optical coherence tomography [OCT], and fundus photography). ... See full document

... with age in a variety of postmitotic metabolically active cells throughout the body and constitute non-degradable end ...a focus of much research in AMD, there is still no defi nitive evidence that the ... See full document

... Fourteen eyes of 14 patients with neovascular AMD who had no significant response or developed resistance to intravitreal ranibizumab (IVR) injections were identified at the National Hospital Organization Tokyo Medical ... See full document

... Twelve RCTs were analyzed in this meta-analysis, which evaluated the effectiveness of intravitreal anti-VEGF in the treatment of neovascular AMD. The superiority remains unclear between IVR and IVB in the ... See full document

... As clinical trials rarely re fl ect the complex- ity of clinical practice, most healthcare providers translate clinical trials recommendation to their best practice by modifying the treatment regimen ... See full document

... The vitreoretinal interface plays an important role in the progression of DR. Vitreolysis involves the use of enzymes to liquefy the vitreous gel and induce posterior vitreous detachment. Vitrase, ie, hyaluronidase ... See full document

... The most commonly used dose of bevacizumab, 1.25 mg, was calculated on the assumption that the dose should be equimolar with respect to ranibizumab; this calculation did not take into account the fact that bevacizumab ... See full document

... of macular thicken- ing causes long-term compromise of macular morphology or visual ...of aflibercept before extending the intertreatment interval to 8 ... See full document

... This was a consecutive, retrospective, observational study to assess visual outcomes in treatment-experienced patients with nAMD who were treated with aflibercept in accordance with the drug label. The study was ... See full document

... Measurements of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in µm, were quanti fi ed at the start of therapy, at 3, 6, and 12 months of anti-VEGF treatment prior to switch, as well as at ... See full document